Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Landscape

Delcath Systems, Inc. (NASDAQ:DCTH) is a medical technology company focused on oncology. It develops and commercializes therapies for the treatment of primary and metastatic liver cancers. The company's main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure. Delcath operates in a competitive landscape with peers like Interpace Biosciences, EOM Pharmaceuticals Holdings, Aeterna Zentaris, and Rennova Health.

In evaluating Delcath's financial performance, the Return on Invested Capital (ROIC) is a key metric. Delcath's ROIC is 3.58%, which is lower than its Weighted Average Cost of Capital (WACC) of 7.61%. This indicates that Delcath is not generating enough returns to cover its cost of capital, which can be a concern for investors looking for efficient capital use.

Comparatively, Interpace Biosciences shows a positive ROIC of 84.16% with a WACC of 9.41%, leading to a favorable ROIC to WACC ratio of 8.94, indicating better capital efficiency than Delcath.

EOM Pharmaceuticals Holdings stands out with an impressive ROIC of 1,140.12% and a WACC of 16.82%, resulting in a ROIC to WACC ratio of 67.77. This suggests that EOM is generating returns far above its cost of capital, highlighting strong capital efficiency and potential for growth. In contrast, Aeterna Zentaris and Rennova Health both have negative ROICs, indicating challenges in generating sufficient returns on their invested capital.